Imagine a World Where metabolic balance is the norm,And patients live without compromise. " We are developing and delivering novel therapies for rare diseases to significantly improve the quality of life for patients and their families. learn more Our lead development program: two Phase 3 programs in congenital and tumor hyperinsulinism. View Our Pipeline Check out stories about how patients and their families address the day-to-day challenges of living with hyperinsulinism. View patient Voices Recent Press Releases view all Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting 05/01/26 Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting 04/21/26 Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting 03/24/26
